Clinical observation of coronary heart disease treated with vinpocetine
10.3760/cma.j.issn.1008-6706.2017.23.024
- VernacularTitle:长春西汀治疗冠心病的临床疗效观察
- Author:
Qinglin HE
1
Author Information
1. 242200,安徽省广德县中医院老年病科
- Keywords:
Coronary artery disease;
Vinpocetine;
Treatment outcome
- From:
Chinese Journal of Primary Medicine and Pharmacy
2017;24(23):3614-3616
- CountryChina
- Language:Chinese
-
Abstract:
Objective To investigate the clinical efficacy of vinpocetine in the treatment of coronary heart disease (CHD).Methods 70 patients with CHD were selected,and they were randomly divided into observation group(35 cases) and control group (35 cases) according to the digital table.The control group received routine treatment,the observation group received vinpocetine therapy combined with fluoxetine on the basis of routine treatment.The changes of serum high sensitivity C reactive protein(hs-CRP) and interleukin 6(IL-6) were observed before and after treatment in the two groups,and the clinical efficacy of the two groups was compared.Results Before treatment,there were no statistically significant differences in hs-CRP and IL-6 levels between the two groups (all P ＞ 0.05).Mter treatment,the serum hs-CRP and IL-6 levels in the observation group were (4.18 ± 0.67) mg/mL,(4.42 ±0.52) pg/mL,respectively,which in the control group were (4.51 ± 0.54) mg/mL,(5.96 ± 0.73) pg/mL,respectively,there were statistically significant differences between the two groups(t =2.376,3.218,all P ＜ 0.05).The effective rate of the observation group was 94.3％,which was significantly higher than 80.0％ of the control group,there was statistically significant difference between the two groups (x2 =4.841,P ＜ 0.05).Conclusion On the basis of routine treatment,vinpocetine in the treatment of CHD can significantly reduce the serum levels of hs-CRP and IL-6,and improve the clinical efficacy.
